Search Results - clinical+and+disease+specializations+%3e+neurology

158 Results

Sort By:

Diagnostic and therapeutic target for primary dysautonomia

Value Proposition:· Diagnostic target for broad primary dysautonomia screening.· Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.Technology DescriptionResearchers at Johns Hopkins have identified a potential diagnostic and therapeutic target for patients with primary dysautonomia....

Published: 5/10/2024 | Inventor(s): Malcolm Brock, Frank Bosmans

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules

Gene therapy for SYNGAP1 encephalopathy and SYNGAP1-related disorders

Unmet Need: SYNGAP1-related Intellectual Disability (SRID, MRD5) is a severe neurodevelopmental disorder (NDD) characterized by encephalopathy, intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy and accounts for 0.5-1% of all NDDs and ~1% of the ~200 million ID cases worldwide (SYNGAP Research Fund, 2020). Supportive management...

Published: 5/10/2024 | Inventor(s): Richard Huganir, Ingie Hong, Yoichi Araki, Richard Johnson

Keywords(s):

Category(s): Clinical and Disease Specializations > Rare Diseases, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Gene Therapies

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 5/9/2024 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors

Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...

Published: 5/10/2024 | Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Controlling homeostatic regulatory circuitry in hypothalamus

Value Proposition· Identifies targets for modulation of tanycyte-derived neurogenesis.· Demonstrates efficacy of small molecule induction of tanycyte-derived neurogenesis.· Combines viral constructs and small molecules to generate specific subtypes of tanycyte-derived neurons.· Applicable to a broad range of hypothalamic...

Published: 5/10/2024 | Inventor(s): Seth Blackshaw, Sooyeon Yoo, Leighton Duncan

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Therapeutic Stem Cells

Conversion of retinal glia into neurons for cell replacement therapy

Value Proposition· Identifies targets for modulation of retinal Muller glia-derived neurogenesis.· Demonstrates efficacy of adeno-associated virus induced retinal Muller glia-derived neurogenesis.· Combines viral constructs and small molecules to generate specific subtypes of retinal Muller glia-derived neurons.· Applicable...

Published: 5/10/2024 | Inventor(s): Seth Blackshaw, Thanh Hoang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Cell Therapies

Artifact Control and Miniaturization of the Safe DC Stimulator for Neural Prostheses

Safe DC Stimulator for Neural ProsthesesJHU Ref #: [C11822] Unmet NeedCurrently, neural prostheses are limited because they excite neurons but cannot efficiently inhibit them. Direct current (DC) can excite, inhibit, or control extracellular potential of target neurons, but DC stimulation is biologically unsafe. The current solution is to direct DC...

Published: 5/9/2024 | Inventor(s): Charles Della Santina, Gene Fridman

Keywords(s): CNS and Neurological Disorders, Disease Indication, Neuroprosthetic Sensing Algorithms, Neuroprosthetics, Prosthetics, Therapeutic Devices, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Medical Devices > Neurostimulation, Technology Classifications > Medical Devices > Prosthetics, Technology Classifications > Medical Devices, Technology Classifications > Medical Devices > Therapeutic Devices

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 5/9/2024 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Neuroscore

NeuroscoreJHU Ref #: C17050Technology Description: Researchers at Johns Hopkins University have developed a product that provides a uniform clinical score for Sturge-Weber Syndrome by determining whether cortical atrophy correlates to clinical severity. The clinical severity was evaluated using computer aided analysis of MRIs to produce laterality scores...

Published: 5/10/2024 | Inventor(s): Anne Comi

Keywords(s):

Category(s): Technology Classifications > Diagnostics > Diagnostic Imaging, Clinical and Disease Specializations > Neurology

PtCu Nanozyme Scavenging ROS for Prevention of Pathologic α-Synuclein Transmission

Description: Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized with misfolded α-synuclein (α-syn) accumulation in Lewy bodies (LB). Although some α-syn mutations have been associated with familial PD, the majority cases are sporadic with unknown etiology. Tremendous efforts have been made to develop...

Published: 5/10/2024 | Inventor(s): Xiaobo Mao, Weiwei He, Yuqing Liu

Keywords(s):

1 2 3 4 5 6 7 8 9 10 ...